Skip to main content
Erschienen in: European Radiology 8/2022

22.03.2022 | Hepatobiliary-Pancreas

Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors

verfasst von: Yi Wang, Gui-Qi Zhu, Chang-Wu Zhou, Na Li, Chun Yang, Meng-Su Zeng

Erschienen in: European Radiology | Ausgabe 8/2022

Einloggen, um Zugang zu erhalten

Abstract

Objectives

To investigate the role of clinicopathological factors and MR imaging factors in risk stratification of combined hepatocellular cholangiocarcinoma (cHCC-CCA) patients who were classified as LR-M and LR-4/5.

Methods

We retrospectively identified consecutive patients who were confirmed as cHCC-CCA after surgical surgery in our institution from June 2015 to November 2020. Two radiologists evaluated the preoperative MR imaging features independently, and each lesion was assigned with a LI-RADS category. Preoperative clinical data were also collected. Multivariate Cox proportional hazards model was applied to separately identify the independent factors correlated with the recurrence of cHCC-CCAs in LR-M and LR-4/5. Risk stratifications were conducted separately in LR-M and LR-4/5. Recurrence-free survival (RFS) rates and overall survival (OS) rates were analyzed by using the Kaplan-Meier survival curves and log-rank test.

Results

A total of 131 patients with single primary lesion which met the 2019 WHO classification criteria were finally included. Corona enhancement, delayed central enhancement, and microvascular invasion (MVI) were identified as predictors of RFS in LR-M. Mosaic architecture, CA19-9, and MVI were independently associated with RFS in LR-4/5. Based on the number of these independent predictors, patients were stratified into favorable-outcome groups (LR-ML subgroup and LR-4/5L subgroup) and dismal-outcome groups (LR-MH subgroup and LR-4/5H subgroup). The corresponding median RFS for LR-ML, LR-MH, LR-5L, and LR-5H were 25.6 months, 8.2 months, 51.7 months, and 18.1 months.

Conclusion

Our study explored the prognostic values of imaging and clinicopathological factors for LR-M and LR-4/5 cHCC-CCA patients, and different survival outcomes were observed among four subgroups after conducting risk stratifications.

Key Points

Corona enhancement, delayed central enhancement, and MVI were identified as predictors of RFS in cHCC-CCAs which were classified into LR-M. Mosaic architecture, CA19-9, and MVI were independently associated with RFS in cHCC-CCAs which were classified into LR-4/5.
Based on the identified risk factors, LR-M and LR-4/5 cHCC-CCA patients could be stratified into two subgroups respectively, with significantly different RFS and OS.
cHCC-CCA patients from LR-M did not always have worse RFS and OS than those from LR-4/5 in some cases.
Anhänge
Nur mit Berechtigung zugänglich
Literatur
1.
Zurück zum Zitat Brunt E, Aishima S, Clavien PA et al (2018) cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68:113–126 Brunt E, Aishima S, Clavien PA et al (2018) cHCC-CCA: consensus terminology for primary liver carcinomas with both hepatocytic and cholangiocytic differentation. Hepatology 68:113–126
2.
Zurück zum Zitat Schizas D, Mastoraki A, Routsi E et al (2020) Combined hepatocellular-cholangiocarcinoma: an update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int 19:515–523 Schizas D, Mastoraki A, Routsi E et al (2020) Combined hepatocellular-cholangiocarcinoma: an update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int 19:515–523
3.
Zurück zum Zitat Xue R, Chen L, Zhang C et al (2019) Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 35:932–947.e938 Xue R, Chen L, Zhang C et al (2019) Genomic and transcriptomic profiling of combined hepatocellular and intrahepatic cholangiocarcinoma reveals distinct molecular subtypes. Cancer Cell 35:932–947.e938
4.
Zurück zum Zitat Joseph NM, Tsokos CG, Umetsu SE et al (2019) Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol 248:164–178 Joseph NM, Tsokos CG, Umetsu SE et al (2019) Genomic profiling of combined hepatocellular-cholangiocarcinoma reveals similar genetics to hepatocellular carcinoma. J Pathol 248:164–178
5.
Zurück zum Zitat Lee HS, Kim MJ, An C (2019) How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol 29:2408–2416 Lee HS, Kim MJ, An C (2019) How to utilize LR-M features of the LI-RADS to improve the diagnosis of combined hepatocellular-cholangiocarcinoma on gadoxetate-enhanced MRI? Eur Radiol 29:2408–2416
6.
Zurück zum Zitat Granata V, Fusco R, Venanzio Setola S et al (2020) Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma. Radiol Oncol 54:149–158 Granata V, Fusco R, Venanzio Setola S et al (2020) Major and ancillary features according to LI-RADS in the assessment of combined hepatocellular-cholangiocarcinoma. Radiol Oncol 54:149–158
7.
Zurück zum Zitat Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373–382 Jeon SK, Joo I, Lee DH et al (2019) Combined hepatocellular cholangiocarcinoma: LI-RADS v2017 categorisation for differential diagnosis and prognostication on gadoxetic acid-enhanced MR imaging. Eur Radiol 29:373–382
8.
Zurück zum Zitat Choi SH, Jeon SK, Lee SS et al (2021) Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI. Eur Radiol. https://doi.org/10.1007/s00330-021-07984-w Choi SH, Jeon SK, Lee SS et al (2021) Radio-pathologic correlation of biphenotypic primary liver cancer (combined hepatocellular cholangiocarcinoma): changes in the 2019 WHO classification and impact on LI-RADS classification at liver MRI. Eur Radiol. https://​doi.​org/​10.​1007/​s00330-021-07984-w
9.
Zurück zum Zitat Choi SH, Lee SS, Park SH et al (2019) LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology 290:388–397 Choi SH, Lee SS, Park SH et al (2019) LI-RADS classification and prognosis of primary liver cancers at gadoxetic acid-enhanced MRI. Radiology 290:388–397
10.
Zurück zum Zitat Beaufrère A, Calderaro J, Paradis V (2021) Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol 74:1212–1224 Beaufrère A, Calderaro J, Paradis V (2021) Combined hepatocellular-cholangiocarcinoma: an update. J Hepatol 74:1212–1224
11.
Zurück zum Zitat Wakizaka K, Yokoo H, Kamiyama T et al (2019) Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol 34:1074–1080 Wakizaka K, Yokoo H, Kamiyama T et al (2019) Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol 34:1074–1080
12.
Zurück zum Zitat Chu KJ, Lu CD, Dong H, Fu XH, Zhang HW, Yao XP (2014) Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases. Eur J Gastroenterol Hepatol 26:192–199 Chu KJ, Lu CD, Dong H, Fu XH, Zhang HW, Yao XP (2014) Hepatitis B virus-related combined hepatocellular-cholangiocarcinoma: clinicopathological and prognostic analysis of 390 cases. Eur J Gastroenterol Hepatol 26:192–199
14.
Zurück zum Zitat Park SH, Lee SS, Yu E et al (2017) Combined hepatocellular-cholangiocarcinoma: gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 46:267–280 Park SH, Lee SS, Yu E et al (2017) Combined hepatocellular-cholangiocarcinoma: gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging 46:267–280
15.
Zurück zum Zitat Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830 Chernyak V, Fowler KJ, Kamaya A et al (2018) Liver imaging reporting and data system (LI-RADS) version 2018: imaging of hepatocellular carcinoma in at-risk patients. Radiology 289:816–830
16.
Zurück zum Zitat Wang X, Wang W, Ma X et al (2020) Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance? Eur Radiol 30:5337–5347 Wang X, Wang W, Ma X et al (2020) Combined hepatocellular-cholangiocarcinoma: which preoperative clinical data and conventional MRI characteristics have value for the prediction of microvascular invasion and clinical significance? Eur Radiol 30:5337–5347
17.
Zurück zum Zitat Lim K, Kwon H, Cho J (2020) Inter-reader agreement and imaging-pathology correlation of the LI-RADS M on gadoxetic acid-enhanced magnetic resonance imaging: efforts to improve diagnostic performance. Abdom Radiol (NY) 45:2430–2439 Lim K, Kwon H, Cho J (2020) Inter-reader agreement and imaging-pathology correlation of the LI-RADS M on gadoxetic acid-enhanced magnetic resonance imaging: efforts to improve diagnostic performance. Abdom Radiol (NY) 45:2430–2439
18.
Zurück zum Zitat Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188 Nagtegaal ID, Odze RD, Klimstra D et al (2020) The 2019 WHO classification of tumours of the digestive system. Histopathology 76:182–188
19.
Zurück zum Zitat Durnez A, Verslype C, Nevens F et al (2006) The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 49:138–151 Durnez A, Verslype C, Nevens F et al (2006) The clinicopathological and prognostic relevance of cytokeratin 7 and 19 expression in hepatocellular carcinoma. A possible progenitor cell origin. Histopathology 49:138–151
20.
Zurück zum Zitat Wu H, Han X, Wang Z et al (2020) Prediction of the Ki-67 marker index in hepatocellular carcinoma based on CT radiomics features. Phys Med Biol 65:235048 Wu H, Han X, Wang Z et al (2020) Prediction of the Ki-67 marker index in hepatocellular carcinoma based on CT radiomics features. Phys Med Biol 65:235048
21.
Zurück zum Zitat Jiang H, Song B, Qin Y et al (2021) Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 31:3638–3648 Jiang H, Song B, Qin Y et al (2021) Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol 31:3638–3648
22.
Zurück zum Zitat Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y (2009) Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation. Radiology 252:605–614 Kitao A, Zen Y, Matsui O, Gabata T, Nakanuma Y (2009) Hepatocarcinogenesis: multistep changes of drainage vessels at CT during arterial portography and hepatic arteriography--radiologic-pathologic correlation. Radiology 252:605–614
24.
Zurück zum Zitat Wei H, Jiang H, Liu X et al (2020) Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma? Eur J Radiol 132:109312 Wei H, Jiang H, Liu X et al (2020) Can LI-RADS imaging features at gadoxetic acid-enhanced MRI predict aggressive features on pathology of single hepatocellular carcinoma? Eur J Radiol 132:109312
25.
Zurück zum Zitat Wei H, Jiang H, Zheng T et al (2021) LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection. Eur Radiol 31:2289–2302 Wei H, Jiang H, Zheng T et al (2021) LI-RADS category 5 hepatocellular carcinoma: preoperative gadoxetic acid-enhanced MRI for early recurrence risk stratification after curative resection. Eur Radiol 31:2289–2302
26.
Zurück zum Zitat Chen J, Zhou J, Kuang S et al (2019) Liver Imaging Reporting and Data System Category 5: MRI predictors of microvascular invasion and recurrence after hepatectomy for hepatocellular carcinoma. AJR Am J Roentgenol 213:821–830 Chen J, Zhou J, Kuang S et al (2019) Liver Imaging Reporting and Data System Category 5: MRI predictors of microvascular invasion and recurrence after hepatectomy for hepatocellular carcinoma. AJR Am J Roentgenol 213:821–830
27.
Zurück zum Zitat Li M, Xin Y, Fu S et al (2016) Corona enhancement and mosaic architecture for prognosis and selection between of liver resection versus transcatheter arterial chemoembolization in single hepatocellular carcinomas >5 cm without extrahepatic metastases: an imaging-based retrospective study. Medicine (Baltimore) 95:e2458 Li M, Xin Y, Fu S et al (2016) Corona enhancement and mosaic architecture for prognosis and selection between of liver resection versus transcatheter arterial chemoembolization in single hepatocellular carcinomas >5 cm without extrahepatic metastases: an imaging-based retrospective study. Medicine (Baltimore) 95:e2458
28.
Zurück zum Zitat Asayama Y, Yoshimitsu K, Irie H et al (2006) Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 238:150–155 Asayama Y, Yoshimitsu K, Irie H et al (2006) Delayed-phase dynamic CT enhancement as a prognostic factor for mass-forming intrahepatic cholangiocarcinoma. Radiology 238:150–155
Metadaten
Titel
Risk stratification of LI-RADS M and LI-RADS 4/5 combined hepatocellular cholangiocarcinoma: prognostic values of MR imaging features and clinicopathological factors
verfasst von
Yi Wang
Gui-Qi Zhu
Chang-Wu Zhou
Na Li
Chun Yang
Meng-Su Zeng
Publikationsdatum
22.03.2022
Verlag
Springer Berlin Heidelberg
Erschienen in
European Radiology / Ausgabe 8/2022
Print ISSN: 0938-7994
Elektronische ISSN: 1432-1084
DOI
https://doi.org/10.1007/s00330-022-08691-w

Weitere Artikel der Ausgabe 8/2022

European Radiology 8/2022 Zur Ausgabe

S3-Leitlinie zu Pankreaskrebs aktualisiert

23.04.2024 Pankreaskarzinom Nachrichten

Die Empfehlungen zur Therapie des Pankreaskarzinoms wurden um zwei Off-Label-Anwendungen erweitert. Und auch im Bereich der Früherkennung gibt es Aktualisierungen.

Fünf Dinge, die im Kindernotfall besser zu unterlassen sind

18.04.2024 Pädiatrische Notfallmedizin Nachrichten

Im Choosing-Wisely-Programm, das für die deutsche Initiative „Klug entscheiden“ Pate gestanden hat, sind erstmals Empfehlungen zum Umgang mit Notfällen von Kindern erschienen. Fünf Dinge gilt es demnach zu vermeiden.

„Nur wer sich gut aufgehoben fühlt, kann auch für Patientensicherheit sorgen“

13.04.2024 Klinik aktuell Kongressbericht

Die Teilnehmer eines Forums beim DGIM-Kongress waren sich einig: Fehler in der Medizin sind häufig in ungeeigneten Prozessen und mangelnder Kommunikation begründet. Gespräche mit Patienten und im Team können helfen.

Wie toxische Männlichkeit der Gesundheit von Männern schadet

08.04.2024 Andrologie Nachrichten

Stark, erfolgreich, allzeit belastbar – das sind Erwartungen, die Jungen und Männer von der Gesellschaft spüren. Das kann sie „toxisch“ werden lassen – und letztlich sogar der Gesundheit schaden, mahnt Dr. Dirk Sander von der Deutschen Aidshilfe.

Update Radiologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.